Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827875 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy
A Phase 1 study, sponsored by AiViva BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04827875 is a Phase 1 study that has completed, run by AiViva BioPharma. The registered enrollment target is 25 participants.
The verdict
NCT04827875, a Phase 1 study, has completed, sponsored by AiViva BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.
Interventions
- DRUG AIV001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-06-23 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04827875
The ClinicalTrials.gov registry entry for NCT04827875 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AiViva BioPharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AIV001 is the first listed.
NCT04827875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04827875 about?
NCT04827875 is a clinical study titled "Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy". To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.
What is the current status of trial NCT04827875?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-06-23. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT04827875?
The interventions under investigation include: AIV001 (DRUG).
Who is sponsoring clinical trial NCT04827875?
This trial is sponsored by AiViva BioPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.